GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Beta

IPA (ImmunoPrecise Antibodies) Beta : N/A (As of Dec. 14, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-14), ImmunoPrecise Antibodies's Beta is Not available.


ImmunoPrecise Antibodies Beta Historical Data

The historical data trend for ImmunoPrecise Antibodies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoPrecise Antibodies Beta Chart

ImmunoPrecise Antibodies Annual Data
Trend Dec14 Dec15 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 0.28 0.33 0.88 0.28

ImmunoPrecise Antibodies Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.16 0.28 0.26 0.05

Competitive Comparison of ImmunoPrecise Antibodies's Beta

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunoPrecise Antibodies's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Beta distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Beta falls into.



ImmunoPrecise Antibodies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


ImmunoPrecise Antibodies  (NAS:IPA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


ImmunoPrecise Antibodies Beta Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoPrecise Antibodies Business Description

Traded in Other Exchanges
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.

ImmunoPrecise Antibodies Headlines

From GuruFocus